老年糖尿病患者SGLT2抑制剂与DPP4抑制剂的肾脏结局比较
基于全国理赔数据库的倾向性评分匹配研究,纳入6354例≥60岁糖尿病新用药者,比较SGLT2抑制剂与DPP4抑制剂对eGFR变化的影响。结果显示SGLT2抑制剂组eGFR下降更慢,且eGFR下降≥20%、≥30%、≥40%的风险显著更低。提示老年糖尿病患者使用SGLT2抑制剂可能对肾脏结局有优势。
要点
- 老年糖尿病患者中,SGLT2抑制剂较DPP4抑制剂延缓eGFR下降。
- SGLT2抑制剂组eGFR下降≥20%、≥30%、≥40%的风险显著更低。
- 亚组分析(年龄、性别、BMI、HbA1c、RAS抑制剂、基线eGFR)结果一致。
核心结论
- 在≥60岁糖尿病患者中,SGLT2抑制剂较DPP4抑制剂使eGFR下降更慢,提示SGLT2抑制剂对老年糖尿病患者肾脏结局可能有益。
研究设计与样本
- 基于全国理赔数据库的回顾性队列研究,纳入6354例≥60岁糖尿病新起始SGLT2抑制剂或DPP4抑制剂治疗者,采用1:4倾向性评分匹配比较eGFR变化。
主要发现
- 匹配后纳入1271例SGLT2抑制剂使用者和5083例DPP4抑制剂使用者,中位年龄68岁(IQR 65-70),男性60.4%,中位eGFR 69.0 ml/min/1.73 m2(IQR 59.1-79.0),中位HbA1c 6.9%(IQR 6.5-7.4)。
- SGLT2抑制剂组eGFR年下降速率为-0.97 ml/min/1.73 m2/年(95% CI -1.24至-0.70),DPP4抑制剂组为-1.83 ml/min/1.73 m2/年(95% CI -1.97至-1.69),交互作用P<.001。
- 基于年龄、性别、BMI、HbA1c水平、RAS抑制剂使用和基线eGFR的亚组分析结果一致。
- SGLT2抑制剂组eGFR较基线下降≥20%、≥30%和≥40%的风险显著低于DPP4抑制剂组。
临床怎么用
- 对于≥60岁糖尿病患者,选择SGLT2抑制剂可能有助于延缓eGFR下降,尤其适用于关注肾脏结局的老年患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While the kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors have attracted much attention, there are limited real-world clinical data examining the effects of SGLT2 inhibitors on kidney function in older individuals. We aimed to compare the kidney outcomes between SGLT2 inhibitor and dipeptidyl peptidase 4 (DPP4) inhibitor use in older adults with diabetes. METHODS: Using a nationwide claims database, we studied 6354 older adults (≥60 years of age) who had diabetes and were newly initiated on SGLT2 inhibitors or DPP4 inhibitors. A 1:4 propensity score matching algorithm was used to compare changes in estimated glomerular filtration rate (eGFR) between SGLT2 inhibitor and DPP4 inhibitor users. The primary outcome was a decrease in the rate of eGFR, which was obtained using a linear mixed-effects model with an unstructured covariance. RESULTS: Following propensity score matching, 6354 individuals including 1271 SGLT2 inhibitor users and 5083 DPP4 inhibitor users {median age 68 years [interquartile range (IQR) 65-70], male 60.4%, median eGFR 69.0 ml/min/1.73 m2 [IQR 59.1-79.0], median haemoglobin A1c [HbA1c] 6.9% [IQR 6.5-7.4]} were analysed. SGLT2 inhibitor users had a slower eGFR decline than did DPP4 inhibitor users [-0.97 ml/min/1.73 m2/year (95% CI -1.24 to -0.70) versus -1.83 ml/min/1.73 m2/year (95% CI -1.97 to -1.69); P for interaction <.001]. This finding remained consistent across subgroups based on age, sex, body mass index, HbA1c level, renin-angiotensin system inhibitor use and baseline eGFR. Additionally, the risk of a ≥20%, ≥30% and ≥40% decrease in eGFR from baseline was significantly lower in SGLT2 inhibitor users than in DPP4 inhibitor users. CONCLUSIONS: Our analysis, utilizing a nationwide epidemiological dataset, demonstrated that the decrease in eGFR was slower in individuals ≥60 years of age with diabetes who were prescribed SGLT2 inhibitors compared with those prescribed DPP4 inhibitors, suggesting a potential advantage of SGLT2 inhibitors for kidney outcomes even in older individuals with diabetes.
引用
- Suzuki Y, Kaneko H, Okada A, et al. Kidney outcomes with SGLT2 inhibitor versus DPP4 inhibitor use in older adults with diabetes. Nephrol Dial Transplant. 2025. PMID: 38991990. doi:10.1093/ndt/gfae158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。